Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine
Executive Summary
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
You may also be interested in...
Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start
With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial.
Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.
Lundbeck Set For 'Transformative' Eptinezumab Launch
The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.